Cargando…

2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome

Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration. We examined the preventative effects of human milk oligosaccharides (HMOs) on epithelial barrier integrity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yeon-Ji, Kim, Han-Hae, Shin, Chul-Soo, Yoon, Jong-Won, Jeon, Seon-Min, Song, Young-Ha, Kim, Kwang-Youn, Kim, Kyungho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145275/
https://www.ncbi.nlm.nih.gov/pubmed/37111064
http://dx.doi.org/10.3390/nu15081845
_version_ 1785034294474833920
author Kim, Yeon-Ji
Kim, Han-Hae
Shin, Chul-Soo
Yoon, Jong-Won
Jeon, Seon-Min
Song, Young-Ha
Kim, Kwang-Youn
Kim, Kyungho
author_facet Kim, Yeon-Ji
Kim, Han-Hae
Shin, Chul-Soo
Yoon, Jong-Won
Jeon, Seon-Min
Song, Young-Ha
Kim, Kwang-Youn
Kim, Kyungho
author_sort Kim, Yeon-Ji
collection PubMed
description Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration. We examined the preventative effects of human milk oligosaccharides (HMOs) on epithelial barrier integrity and intestinal inflammation in an interleukin (IL)-6-induced cell model and dextran sodium sulfate (DSS)-induced acute mouse colitis model. HMOs including 2′-fucosyllactose (FL) and 3-FL and positive controls including fructooligosaccharide (FOS) and 5-acetylsalicylic acid (5-ASA) were orally administrated once per day to C57BL/6J mice with colitis induced by 5% DSS in the administered drinking water. 2′-FL and 3-FL did not affect the cell viability in Caco-2 cells. Meanwhile, these agents reversed IL-6-reduced intestinal barrier function in Caco-2 cells. Furthermore, 2′-FL and 3-FL reversed the body weight loss and the remarkably short colon lengths in DSS-induced acute colitis mice. Moreover, 2′-FL and 3-FL obviously protected the decreasing expression of zonula occluden-1 and occludin in colon tissue relative to the findings in the DSS-treated control group. 2′-FL and 3-FL significantly reduced IL-6 and tumor necrosis factor-α levels in serum relative to the control findings. The summary of these results shows that HMOs prevent colitis mainly by enhancing intestinal barrier function and advancing anti-inflammatory responses. Therefore, HMOs might suppress inflammatory responses and represent candidate treatments for IBD that protect intestinal integrity.
format Online
Article
Text
id pubmed-10145275
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101452752023-04-29 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome Kim, Yeon-Ji Kim, Han-Hae Shin, Chul-Soo Yoon, Jong-Won Jeon, Seon-Min Song, Young-Ha Kim, Kwang-Youn Kim, Kyungho Nutrients Article Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration. We examined the preventative effects of human milk oligosaccharides (HMOs) on epithelial barrier integrity and intestinal inflammation in an interleukin (IL)-6-induced cell model and dextran sodium sulfate (DSS)-induced acute mouse colitis model. HMOs including 2′-fucosyllactose (FL) and 3-FL and positive controls including fructooligosaccharide (FOS) and 5-acetylsalicylic acid (5-ASA) were orally administrated once per day to C57BL/6J mice with colitis induced by 5% DSS in the administered drinking water. 2′-FL and 3-FL did not affect the cell viability in Caco-2 cells. Meanwhile, these agents reversed IL-6-reduced intestinal barrier function in Caco-2 cells. Furthermore, 2′-FL and 3-FL reversed the body weight loss and the remarkably short colon lengths in DSS-induced acute colitis mice. Moreover, 2′-FL and 3-FL obviously protected the decreasing expression of zonula occluden-1 and occludin in colon tissue relative to the findings in the DSS-treated control group. 2′-FL and 3-FL significantly reduced IL-6 and tumor necrosis factor-α levels in serum relative to the control findings. The summary of these results shows that HMOs prevent colitis mainly by enhancing intestinal barrier function and advancing anti-inflammatory responses. Therefore, HMOs might suppress inflammatory responses and represent candidate treatments for IBD that protect intestinal integrity. MDPI 2023-04-12 /pmc/articles/PMC10145275/ /pubmed/37111064 http://dx.doi.org/10.3390/nu15081845 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Yeon-Ji
Kim, Han-Hae
Shin, Chul-Soo
Yoon, Jong-Won
Jeon, Seon-Min
Song, Young-Ha
Kim, Kwang-Youn
Kim, Kyungho
2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title_full 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title_fullStr 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title_full_unstemmed 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title_short 2′-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome
title_sort 2′-fucosyllactose and 3-fucosyllactose alleviates interleukin-6-induced barrier dysfunction and dextran sodium sulfate-induced colitis by improving intestinal barrier function and modulating the intestinal microbiome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145275/
https://www.ncbi.nlm.nih.gov/pubmed/37111064
http://dx.doi.org/10.3390/nu15081845
work_keys_str_mv AT kimyeonji 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT kimhanhae 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT shinchulsoo 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT yoonjongwon 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT jeonseonmin 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT songyoungha 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT kimkwangyoun 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome
AT kimkyungho 2fucosyllactoseand3fucosyllactosealleviatesinterleukin6inducedbarrierdysfunctionanddextransodiumsulfateinducedcolitisbyimprovingintestinalbarrierfunctionandmodulatingtheintestinalmicrobiome